NTLA-2002

About Intellia Therapeutics

Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9-based therapeutics, aiming to cure severe genetic and other diseases through precise genome editing. The company has achieved significant milestones, including the first-ever clinical data demonstrating in vivo CRISPR genome editing in humans. Its strategy leverages a dual-platform approach, developing both in vivo (systemically administered) and ex vivo (cell-based) therapies, with key partnerships including Regeneron and Novartis to advance its pipeline.

About Intellia Therapeutics

Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9-based therapeutics, aiming to cure severe genetic and other diseases through precise genome editing. The company has achieved significant milestones, including the first-ever clinical data demonstrating in vivo CRISPR genome editing in humans. Its strategy leverages a dual-platform approach, developing both in vivo (systemically administered) and ex vivo (cell-based) therapies, with key partnerships including Regeneron and Novartis to advance its pipeline.

Therapeutic Areas